(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott released the following statement on the Senate Special Committee on Aging hearing, “The Complex Web of Prescription Drug Prices, Part III: Examining Agency Efforts to Further Competition and Increase Affordability:” “We applaud the...
PBMs are an important link in the drug supply and payment chain that includes manufacturers, wholesalers, physicians, pharmacies and Pharmacy Service Administrative Organizations, all working to get therapies to patients....
(Washington, D.C.) — As the Energy and Commerce Subcommittee on Health examines ways to bring more transparency to prescription drug prices, the Pharmaceutical Care Management Association (PCMA) is confirming its principles on transparency in the prescription drug supply chain. PCMA commends the Subcommittee’s work to bring...
Appearing recently before the Senate Finance Committee, executives for pharmacy benefit managers had the opportunity to set the record straight on their value, including their role as the only check against drug manufacturers’ pricing powers. ...
Prescription drug list prices in the United States continue to be a source of frustration for patients and policymakers alike. The administration is pushing forward with new ideas for lower list prices and lower costs for consumers. As the only entity in the prescription drug...
As the debate on high-cost prescription drugs continues and policymakers seek solutions to reduce out-of-control prices for consumers, the Pharmaceutical Care Management Association (PCMA) today is announcing the launch of a new, multi-faceted digital public affairs campaign OnYourRxSide. The campaign is designed to increase awareness of the...
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on reports that twenty-eight drugmakers are set to raise prescription drug prices in 2019: “Today’s news underscores the fact that drugmakers alone set and raise prescription drug prices. Given...
The drug giants moved in near-perfect synchronicity, raising prices for their top-selling arthritis treatments as though they were opposite-corner gas stations bumping up the price of unleaded....
First, rebates are directly responsible for lowering Part D premiums and program spending....
Pfizer Inc. will likely go back to “business as normal” for drug price increases...